Addiction Toxicology Case Conference - August 2026

Dr. Tim Wiegand is the Director of Toxicology Consults and President of CMO Medicine and Toxicology & Addiction Consulting. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Dr. Emily Brunner is a board-certified family medicine physician and distinguished fellow in addiction medicine, specializing in trauma-informed, compassionate care for substance use disorders. She serves as Medical Director of Gateway Recovery and Recovering Hope and conducts trainings for the Hazelden Betty Ford Foundation. A recognized leader, she has held positions with the Minnesota Society of Addiction Medicine and currently serves on the national board of the American Society of Addiction Medicine. Dr. Brunner is a passionate advocate for expanding access to medications for opioid use disorder and improving care for patients with substance use disorders across the healthcare system. Named a Top Doctor in addiction medicine by Minnesota Magazine in 2020 and 2021, she also has a clinical interest in internet gaming and gambling disorders.

Dr. Fong is a Professor of Psychiatry at the Jane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA.  He is board certified in adult and addiction psychiatry.

He is the co-director of the UCLA Gambling Studies Program.   The purpose of this program is to examine the clinical characteristics of gambling disorder in order to develop effective, evidence-based prevention and treatment strategies.  

Dr. Fong is also a member of the Steering Committee of the UCLA Center for Cannabis and Cannabinoids whose mission is to address the most pressing questions related to the impact of cannabis legalization through rigorous scientific study and discourse across disciplines.

He is the senior attending psychiatrist for the UCLA Sports Psychiatry Service which provides leading edge psychiatric care to athletes, coaches and families.

Lastly, he is the President, of the American Academy of Addiction Psychiatry.